In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smith & Nephew plc

http://www.smith-nephew.com

Latest From Smith & Nephew plc

Medtech 100: Big Three Companies Lead From The Front With Medtech Back On Solid Growth Footing

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Medtech 100 Commercial

The Medtech 100 Ranking: A Successful Year But Industry Must Tread Carefully In 2023

Medtech Insight’s just-published ranking of the leading global medtechs based on revenues reported for fiscal 2021 reveals a picture of an industry overwhelmingly in growth, despite – or in some cases because of – the persistent effects of the pandemic.

Medtech 100 Commercial

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Outlook 2023 Sales & Earnings

Finance Watch: No New IPOs, But Two Firms Take The SPAC Route

Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.

Financing Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Other Names / Subsidiaries
    • Acufex Microsurgical, Inc.
    • ADERMA
    • ArthroCare Corporation
    • Atracsys Sàrl
    • Blue Belt Holdings, Inc.
    • Blue Belt Technologies
    • Ceterix Orthopaedics, Inc.
    • EuroCiencia Colombia
    • Healthpoint Biotherapeutics
    • Kalypto Medical
    • Leaf Healthcare, Inc.
    • LifeModeler
    • Nucryst Pharmaceuticals
    • Osiris Therapeutics, Inc.
    • Plus Orthopedics
    • Richards Medical Company
    • Rotation Medical, Inc.
    • Tenet
UsernamePublicRestriction

Register